Latest filing published 25 Nov 2024 for Cyclerion Therapeutics, Inc., €526k.
Filing timeline
BuySaleInsider track record
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Slate Path Capital LP: trading record in brief
All filings by Slate Path Capital LP on record concern Korsana Biosciences, Inc. We count 2 filings; the first trade dates from 3 June 2021 and the latest from 21 November 2024.
In open-market terms, that means 1 purchase worth €2.5M on one side and 1 sale worth €526k on the other. Netting one side against the other leaves €1.9M of net buying. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. 2024 to date brings no purchases and 1 sale.
On 25 November 2024 came the latest disclosure, an open-market sale for €526k in Korsana Biosciences, Inc. The clock since the last published purchase (7 June 2021) now reads 1,981 days. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Slate Path Capital LP
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 357,880 shares@ US$1.55119.6% of flowCommon Stock, no par valueSEC:0000902664-24-006775:0
- 961,538 shares@ US$3.1282.4% of flowCommon Stock, no par valueSEC:0000902664-21-003032:0Canonical exit: 1 Sept 2021 (T+90)
2 of 2 declarations
